Recognizing the importance of addressing all aspects of disease, we started our joint rheum-derm psoriatic disease clinic at Northwestern shortly after I arrived at the institution, and it has been a tremendous success.
Dr. John Cush RheumNow
4 years 5 months ago
SLE study from BC, Canada shows that among 3062 incident #SLE patients 96% received antimalarial (AM) Rx with only 40% adherent. Over a 6.4 yr F/U, 242 (8%) died. AM adherence was assoc w/ a 71% and 83% lower risk of death https://t.co/S9LsDaSZNx https://t.co/lFWZJTh367
Dr. John Cush RheumNow
4 years 5 months ago
Ixekizumab in 1401 #PSA pts w/ 2248 Pt-Yrs exposure showed Serious AE in 134 pts. Most common AEs were nasopharyngitis & URI. Incidence of SAE (≤1.2/100PY), cancer (0.7/100PY), IBD (0.1/00PY), depression (1.6/100PY) were low. #PSAlways https://t.co/YGGj4XCQDM
Arthritis & Rheumatology has publish an ACR Subcommittee report on how the COVID-19 pandemic affected fellows and their training.
Dr. John Cush RheumNow
4 years 5 months ago
Retrospective study of 1144 consecutive inflammatory myositis (IIM) pts shows a 2.3% risk of venous thrombolic events. 54% of VTE occurred within 6 mos of IIM Dx. Predictors included malignancy, infection, longer steroid use , higher Dz activity https://t.co/DCH4Iuy2FS https://t.co/uNc6i6L7JJ
Tumor necrosis factor (TNF) inhibitors for rheumatoid arthritis were linked with a lower risk of Alzheimer's disease and related dementia, but only in people with cardiovascular disease, data from the DREAM (Drug Repurposing for Effective Alzheimer's Medicines) study showed.
Dr. John Cush RheumNow
4 years 5 months ago
Cell has a novel analysis using single-cell analysis of skin/blood from 56 controls & 97 diffuse systemic sclerosis pts, finding stromal abnormalities in LGR5+-scleroderma-assoc fibroblasts (ScAFs). ScAFs are decreased early & progressively https://t.co/Khxejd1fnq https://t.co/OrMAJnPTZt
Dr. John Cush RheumNow
4 years 5 months ago
ArthritisPower study of 332 #PsA pts finds patients are most bothered by joint pain, MSK pain & fatigue. Patients prefer oral, QD meds; 3/4 want Rx that improved joints vs skin; and would prefer to avoid MTX https://t.co/WYqWgoimOT https://t.co/RgGeCKrpT1
Dr. John Cush RheumNow
4 years 5 months ago
2020 Pt preferences survey- 137 #PsA pts most took TNFi (30%), IL-17i (20%), MTX (10%). From 2018 to 2020 a signif incr in IL-17i & PDE4 inhib. Pts want Rx for damage (80%), ADL (71%), & pain (70%) https://t.co/2dyIuQubh5 https://t.co/sFbtRj0Lbv
Dr. John Cush RheumNow
4 years 5 months ago
ICYMI: Deucravacitinib, TYK2 inhib, studied in phase II trial 203 active PsA pts randomised to PBO, or DEUC 6 mg or 12 mg qd. At wk 16 ACR-20 responses were significantly higher with DEUC 6mg (53%, p=0.0134) and 12 mg (63%, p=0.0004) vs PBO. https://t.co/UOPteZY0g8 https://t.co/Xw3ZSPWeE0
Dr. John Cush RheumNow
4 years 5 months ago
ICYMI: Differences between Palpated & Ultrasound Joint exams in 155 #PSA patients. 5616 joints - found 18.5% tender, 9.8% swollen, 20.4% w/ US GS ≥ 2 and 5.2% had US PD ≥ 1. Joints that were both tender and swollen more likely to have GS ≥ (44%) https://t.co/M6y5Gezhjs https://t.co/HYoI3pExRm
Dr. John Cush RheumNow
4 years 5 months ago
ICYMI:The Enthesitis Challenge in Psoriatic Arthritis
A colleague of mine told me an interesting story about how her father, who was a doctor, misdiagnosed his wife with fibromyalgia when she actually had PsA with enthesitis all along.
Read more...
https://t.co/bSYdtlL41J https://t.co/gKKdWTvyMB
Dr. John Cush RheumNow
4 years 5 months ago
ICYMI: TNR Recap: What Patients Say About PsA
Watch Tuesday Nite Rheumatology, held on 4/5/22,which featured a Patient Perspectives panel discussion, hosted by Dr. Jack Cush.
PsA Panelists included:
- Tena Brown
- Christine Lindsay
- Ashley Krivohlavek
https://t.co/FyjnzrtKqp https://t.co/uEHsoAwHLY
